AdaptHealth reported third-quarter 2026 net revenue of $745.6 million, up 10.9% from a year earlier, but a $184.8 million pre-tax goodwill write-down produced a net loss. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance but lowered its free cash flow guidance, and it cleared the Hart-Scott-Rodino waiting period for the pending $235.0 million sale of its Diabetes Health business.
Q3 net revenue $745.6 million vs. $672.4 million; organic revenue growth of 12.8%
Q3 Adjusted EBITDA $141.9 million vs. $146.1 million, down 2.9%
2026 guidance: revenue raised to $2.88-$2.90 billion; Adjusted EBITDA raised to $510-$525 million; free cash flow cut to $50-$75 million from $80-$120 million
Diabetes Health sale for $235.0 million in cash expected to close in early 2027
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From AdaptHealth Corp.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$3.24B
-0.5%
$-0.52
-185.2%
-2.2%
FY2024
$3.26B
+1.9%
$0.61
—
2.8%
FY2023
$3.20B
+7.7%
$-5.31
-1709.1%
-21.2%
FY2022
$2.97B
+21.0%
$0.33
-50.7%
2.3%
FY2021
$2.45B
+132.4%
$0.67
—
6.4%
Frequently asked questions
When is AdaptHealth's next earnings date?
AdaptHealth has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did AdaptHealth earn last quarter?
For the quarter ended Sep 2026, AdaptHealth reported diluted EPS of $-1.13 (-764.7% year over year) on revenue of $745.65M (+10.9%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.